Search research articles
Contact Us
Filters
Showing results (41-50 of 181) with videos related to
Page
of 19
Sort By:
Acta Oncologica (Stockholm, Sweden)
|
June 27, 2019
Bringing Europe together in building clinical evidence for proton therapy - the EPTN-ESTRO-EORTC endeavor
Damien C Weber, Cai Grau, Pei S Lim, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2011
Changes in pulmonary function up to 10 years after locoregional breast irradiation
Katrien Erven, Caroline Weltens, Kristiaan Nackaerts, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2018
Radiation Therapy Research: A Global Analysis 2001-2015
Ajay Aggarwal, Grant Lewison, Danielle Rodin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 15, 2014
In search of the economic sustainability of Hadron therapy: the real cost of setting up and operating a Hadron facility
Barbara Vanderstraeten, Jan Verstraete, Roger De Croock, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 9, 2014
In reply to de Ruysscher et al
Barbara Vanderstraeten, Wilfried De Neve, Yolande Lievens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 5, 2002
Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study
Dirk De Ruysscher, Yolande Lievens, Paul Van den Brande, et al.
The Lancet. Oncology
|
January 8, 2020
How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement
Yolande Lievens, Noémie Defourny, Julieta Corral, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 10, 2021
ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium<sup>☆</sup>
Florian Charlier, Thomas Descamps, Yolande Lievens, et al.
JCO Global Oncology
|
July 19, 2022
Adopting Health Economic Research in Radiation Oncology: A Perspective From Low- or Middle-Income Countries
Shwetabh Sinha, Sarbani Ghosh Laskar, Tabassum Wadasadawala, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 8, 2009
Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT
Evelyn Van de Werf, Yolande Lievens, Jan Verstraete, et al.
Page
of 19
Search research articles
Search
Showing results (41-50 of 181) with videos related to
Sort By:
Page
of 19
Acta Oncologica (Stockholm, Sweden)
|
June 27, 2019
Bringing Europe together in building clinical evidence for proton therapy - the EPTN-ESTRO-EORTC endeavor
Damien C Weber, Cai Grau, Pei S Lim, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 15, 2011
Changes in pulmonary function up to 10 years after locoregional breast irradiation
Katrien Erven, Caroline Weltens, Kristiaan Nackaerts, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 7, 2018
Radiation Therapy Research: A Global Analysis 2001-2015
Ajay Aggarwal, Grant Lewison, Danielle Rodin, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 15, 2014
In search of the economic sustainability of Hadron therapy: the real cost of setting up and operating a Hadron facility
Barbara Vanderstraeten, Jan Verstraete, Roger De Croock, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 9, 2014
In reply to de Ruysscher et al
Barbara Vanderstraeten, Wilfried De Neve, Yolande Lievens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 5, 2002
Dose-intensified accelerated vindesine-ifosfamide-cisplatin (VIP) chemotherapy followed by high-dose accelerated hyperfractionated radiotherapy in patients with pathologically proven stage IIIB non-small cell lung cancer: a feasibility study
Dirk De Ruysscher, Yolande Lievens, Paul Van den Brande, et al.
The Lancet. Oncology
|
January 8, 2020
How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement
Yolande Lievens, Noémie Defourny, Julieta Corral, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 10, 2021
ProCaLung - Peer review in stage III, mediastinal node-positive, non-small-cell lung cancer: How to benchmark clinical practice of nodal target volume definition and delineation in Belgium<sup>☆</sup>
Florian Charlier, Thomas Descamps, Yolande Lievens, et al.
JCO Global Oncology
|
July 19, 2022
Adopting Health Economic Research in Radiation Oncology: A Perspective From Low- or Middle-Income Countries
Shwetabh Sinha, Sarbani Ghosh Laskar, Tabassum Wadasadawala, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 8, 2009
Time and motion study of radiotherapy delivery: Economic burden of increased quality assurance and IMRT
Evelyn Van de Werf, Yolande Lievens, Jan Verstraete, et al.
Page
of 19